# Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

> **NCT04585893** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Multicentric Castleman Disease

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04585893
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-22
- **Primary completion:** 2024-08-30
- **Final completion:** 2026-06-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585893, "Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04585893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*